Quinacrine sterilization: An assessment of risks for ectopic pregnancy, birth defects and cancer

Advances in Contraception

Volumn 14, Issue 2, 1998, Pages 81-90

  Kessel, E ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; MEPACRINE;

BIRTH DEFECT; CANCER; CANCER RISK; CLINICAL TRIAL; DRUG SAFETY; DRUG TISSUE LEVEL; ECTOPIC PREGNANCY; FEMALE; FEMALE STERILIZATION; HEALTH CARE COST; HUMAN; INFLAMMATION; INTRAVAGINAL DRUG ADMINISTRATION; MODEL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRENATAL DRUG EXPOSURE; PROBABILITY; REVIEW; RISK BENEFIT ANALYSIS; SCAR FORMATION; TERATOGENICITY; UTERINE TUBE MUCOSA;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; DRUG IMPLANTS; FEMALE; HUMANS; MUTAGENS; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY, ECTOPIC; QUINACRINE; RISK FACTORS; STERILIZATION, REPRODUCTIVE;

EID: 0031782938     PISSN: 02674874     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006556331674     Document Type: Review

References (37)

1. Sadik N The State of World Population 1997. United Nations Population Fund, New York, 1997.
2. State Family Planning Commission. Population and Family Planning in China Beijing. 1997.
3. Central Bureau of Statistics (CBS) [Indonesia] and State Ministry of Population/National Family Planning Coordinating Board (NFPCB) and Ministry of Health (MOH) and Macro International Inc. (MI). 1995 Indonesia Demographic and Health Survey 1994. Calverton, Maryland: CBS and MI. p. 76, Table 5.2.2.
4. General Statistical Office. 1994 Inter-Censal Demographic Survey. Statistical Publishing House, Hanoi, May 1995.
5. National Population Council (NPC) and Macro International Inc. (MI). Egypt Demographic and Health Survey 1996. Calverton. Maryland. NPC and MI: 1997.
6. Klitsch M Sterilization without surgery Int Fam Plann Perspect 1982;8:101-4.
7. Zipper J, Cole LP, Goldsmith A, Wheeler R, Rivera M, Quinacrine hydrochloride pellets: preliminary data on a nonsurgical method of female sterilization Int J Gynaecol Obstet. 1980;18:265-9.
8. Kessel E. 100,000 quinacrine sterilizations. Adv Contracept. 1996;12:69-76.
9. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Taylor LR, Trussell V. The risk of ectopic pregnancy after tubal sterilization. N Engl J Med. 1997;336:762-7.
10. Hieu DT, Tan TT, Tan DN, Nguyet PT, Than P, Vinh DQ. 31 781 cases of non-surgical female sterilisation with quinacrine pellets in Vietnam. Lancet. 1993;342:213-7.
11. Franks AL, Beral V, Cates W, Hogue CJR. Contraception and ectopic pregnancy risk. Am J Obstet Gynecol. 1990;163:1120-3.
12. Sokal DC, Zipper J, King T. Transcervical quinacrine sterilization: clinical experience Int J Gynecol Obstet. 1995;51(suppl):556-69.
13. Peterson HB, Zhisen X, Hughes J, et al. The risk of pregnancy after tubal sterilization: finding from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol. 1996;174:1161-70.
14. Soroodi-Maghaddam S. Preliminary report on a clinical trial of the quinacrine pellet method for nonsurgical female sterilization in Iran. Int Fam Plann Perspect. 1996;22:122-3, 127.
15. Bairagi NR, Mullick BC, Kessel E, Mumford SD. Comparison of the efficacy of intrauterine diclofenac and ibuprofen pellets as adjuvants to quinacrine nonsurgical female sterilization. Adv Contracept. 1995;11:303-8.
16. Institute for Development Training. Female voluntary non-surgical sterilization: The quinacrine method. Module 12 of Training Course in Women's Health. Institute for Development Training, Chapel Hill, 1996.
17. Rock JA, Parmley TH, King TM, Laufe LE, Su BC. Endometriosis and the development of tuboperitoneal fistulas after tubal ligation. Fertil Steril. 1981;35:16-20.
18. Blake DA, Dubin NH, Blasé MC, Parmley TM, Stetten G, King TM. Teratologic and mutagenic studies with intrauterine quinacrine hydrochloride. In: Zatuchni GI, Shelton JD, Goldsmith A, Sciarra JJ, eds. Female Transcervical Sterilization. Philadelphia, Harper and Row, 1983, p. 71-88.
19. Bartsch H, Malaveille C. Prevalence of genotoxic chemicals among animal and human carcinogens evaluated in the IARC Monograph Series. Cell Biol Toxicol. 1989;5(2):115-27.
20. Wiltse J, Dellarco VL. U.S. Environmental Protection Agency Guidelines for carcinogenic risk assessment: Past and future Mutation Res. 1996;365:3-15.
21. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science. 1990;249:1007-11.
22. Tice RR, Griffith J, Recio L. An evaluation of the mutagenicity and carcinogenicity of quinacrine. Family Health International 1990. Research Triangle Park, NC. pp. 27.
23. Fitzhugh OG, Nelson AA, Calvery HO. The chronic toxicity of quinacrine (atabrine). J Pharmacol Exp Ther. 1945;85:207-21.
24. Dabancens A, Zipper J, Guerrero A. Quinacrine and copper, compounds with anticonceptive and antineoplastic activity. Contraception. 1994;50:243-51.
25. Sokal DC, Zipper J, Guzman-Serani R, Aldrich TE. Cancer risk among women sterilized with transcervical quinacrine hydrochloride pellets, 1988-1991. Fertil Steril. 1995;64:324-34.
26. Cahn RS, Dermer OC. Introduction to Chemical Nomenclature, 5th ed. Butterworths, London, 1979, 245 pp.
27. Claxton LD, Stead AG, Walsh D. An analysis, by chemical class of Salmonella mutagenicity tests as predictors of animal carcinogenicity. Mutation Res. 1988; 205: 197-225.
28. Commoner B. Vithayathil AU, Dolara P, Nair S, Madyastha P, Cuca GC. Formation of mutagens in beef extract during cooking. Science. 1978;201:913-16.
29. Fujita Y, Wakabayashi K, Nagao M, Sugimura T. Implication of hydrogen peroxide in the mutagenicity of coffee. Mutation Res. 1985,144:227-30.
30. Shannon JA, Earle DP Jr, Brodie BB, Taggart JV, Berliner RW. The pharmacological basis for the rational use of atabrine in the treatment of malaria. J Pharmacol Exp Ther. 1944;81:307-30.
31. Dubin NH, Parmley TH, DiBlasi MC et al. Pharmacology of quinacrine hydrochloride with emphasis on its use as a tubal occluding agent In: Zatuchni GI, Shelton JD, Goldsmith A, Sciarra JJ, eds. Female Transcervical Sterilization. Philadelphia, Harper and Row. 1983. pp. 60-70.
32. Laufe LE, Sokal DC, Cole LP, Shoupe D, Schenken RS. Phase I prehysterectomy studies of the transcervical administration of quinacrine pellets. Contraception. 1996;54:181-6
33. Patek E. Quinacrine hydrochloride: Review and mode of action of an antimalarial, used as an occlusive agent for transvaginal human sterilization. Acta Obstet Gynecol Scand. 1979;58:561-4.
34. Gold LS, Bernstein L, Magaw R, Slone TH. Interspecies extrapolation in carcinogenesis: prediction between rats and mice. Environ Health Perspect. 1989;211-19.
35. Ames BN, Gold LS Too many rodent carcinogens: mitogenesis increases mutagenesis. Science. 1990;249:970-1.
36. Godal T. Fighting the parasites of poverty: public research, private industry, and tropical diseases. Science. 1994,264:1864-6
37. Kawachi I, Colditz GA, Hankinson S, Long-term benefits and risks of alternative methods of fertility control in the United States. Contraception. 1994;50:1-16.